 |
Pfizer abandons plan to split into twoUS drugmaker Pfizer said on Monday it had decided not to separate into two publicly traded companies by separating its low-growth generics from its patent-protected branded medicines. Instead, with the two operating as separate bu More… |
 |
Top biotech industry players to meet at BioJapanKey players from the biotech industry from more than 30 countries are set to gather at Asia's leading biotechnology partnering event in Japan in October. The 17th edition of BioJapan 2015 will run from Octo More… |
|
Top biotech industry players to meet at BioJapanKey players from the biotech industry from more than 30 countries are set to gather at Asia's leading biotechnology partnering event in Japan in October. The 17th edition of BioJapan 2015 will run from Octo More… |
 |
GSK extends $2.6bn offer to key partnerGlaxoSmithKline has extended its $2.6 billion offer to buy long-time partner Human Genome Sciences until the end of June as it battles the US biotech company's reluctant management. The price remains unchanged at $13 a share under the More… |
 |
$1-5bn seen optimal for biotech M&ABiotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough environment, Ernst & Young said. Big pharma companies are More… |
